Impact of Pre-Existing Cardiovascular and Metabolic Conditions on the Development of Heart Failure After Paclitaxel Therapy　― Real-World Study Based on a Nationwide Claims Database in Japan ―

Background: The early detection and treatment of cancer have led to an aging population of cancer survivors, and mortality rates from cardiovascular diseases are increasing. The incidence of heart failure (HF) after treatment with paclitaxel (PTX), a microtubule polymerization promoter and cardiotoxic anticancer agent, is low and the risk factors for post-PTX HF remain unclear. A history of heart disease has been suggested as a potential cardiovascular risk factor in cancer survivors. Using the JMDC database of real-world medical data in Japan, we investigated whether heart and lifestyle-related diseases affect the onset of HF after PTX treatment.